Targeting-evidence map
Define intended cells or tissue, route, delivery mechanism and functional endpoint before selecting readouts.
Scientific advisory / tLNP / RNA
Targeted LNP & RNA analytics
Connect RNA quality and formulation attributes to evidence for delivery and function in the intended target cells.
The analytical question
Define what the result means.
Targeted lipid nanoparticles (tLNPs) require a precise definition of targeting. Ligand-mediated recognition, composition-dependent tropism and a desired tissue distribution are different hypotheses. We help translate the intended payload, target cell and functional outcome into a coherent analytical study plan.
- RNA identity, amount and integrityTarget quantification is one part of RNA characterization. Sequence, molecular integrity, relevant impurities and, where applicable, capping or poly(A) attributes require complementary measurements.
- Particle and formulation attributesLipid identity and content, size distribution, encapsulation and free versus associated RNA address formulation quality. Encapsulation does not establish RNA integrity or biological activity.
- Targeting and productive deliveryTissue distribution, cell association, uptake, intracellular delivery and expression, silencing or editing are separate endpoints. The evidence plan should distinguish each relevant step.
Potential workstreams
How we can help.
The final scope is agreed for the product, development stage and scientific decision.
RNA assay strategy
Assess RT-qPCR or RT-dPCR alongside orthogonal approaches for payload integrity, identity and relevant RNA impurities.
Formulation characterization
Identify candidate physicochemical assays and dependencies between RNA recovery, particle disruption and analytical readout.
Ligand-bearing systems
Where applicable, plan ligand identity, conjugation, accessible presentation and binding assessment without equating binding with intracellular function.
Controls and candidate comparisons
Define appropriate nontargeted or ligand controls, target-positive and target-negative comparisons, and specificity assessments.
Integrated interpretation
Review provider-generated results across RNA, formulation and biological studies; document unresolved questions and follow-up priorities.
Consulting deliverables
What you receive.
Depending on the agreed engagement, outputs can include:
- A targeting hypothesis and evidence map
- An RNA/formulation assay and control matrix
- A candidate-comparison and stability study brief
- Requirements for separately scoped laboratory studies
- An integrated data-interpretation framework
These are proposed advisory outputs, not claims of completed experiments or validated performance. Laboratory execution and provider responsibilities are scoped separately.
Scientific boundaries
Fluorescence, tissue accumulation or ligand binding alone does not demonstrate productive delivery to the intended cells. Animal tropism does not establish human targeting. Delivery efficiency, tissue exclusivity and therapeutic efficacy require product-specific evidence.
Common questions
Does high encapsulation mean the RNA will work?
No. Encapsulation, RNA integrity, intracellular release and biological activity are different attributes. A formulation can perform differently across these readouts.
Are all RNA payloads assessed in the same way?
No. The relevant attributes depend on the payload and intended use. For example, attributes associated with mRNA capping or poly(A) do not apply identically to every RNA modality.
Selected references
These sources inform the scientific principles. They do not establish company credentials or endorse Genometrion.
- Cheng et al. — Selective organ targeting nanoparticles
- Primary study — LNP delivery across cell subtypes
- ICH Q14 — Analytical procedure development
Editorial review: 31 October 2026.
Related services
Start with the question
Complex therapies.
Clearer analytical decisions.
Define the scientific question behind your project. We can discuss the evidence, methods and practical next steps.
Scientific enquiries
Let’s talk about your project.
A brief, nonconfidential outline is a useful starting point.
contact@genometrion.comEmail GenometrionOpens your email application. Contact details and enquiry guidance.